Caris Life Sciences Publishes Study Validating Caris AI Insights for Temozolomide Benefit in Glioblastoma Patients
Rhea-AI Summary
Caris Life Sciences (NASDAQ: CAI) published a peer-reviewed study validating an AI-derived signature that predicts MGMT promoter methylation and temozolomide (TMZ) benefit in glioblastoma (GBM) patients.
The signature was developed from a clinico-genomic dataset of 5,841 patients and evaluated prospectively in >3,400 cases, showing high concordance with pyrosequencing and stratifying overall survival in TMZ-treated, IDH-wild type GBM.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- Peer-reviewed validation of AI signature using clinical data
- Model developed on a clinico-genomic dataset of 5,841 patients
- Prospective evaluation in >3,400 additional cases
- High concordance with pyrosequencing-based MGMT assessment
- Stratified overall survival in TMZ-treated, IDH-wild type GBM
Negative
- Findings apply to customers with access to Caris AI Insights (proprietary access)
- Clinical utility limited to MGMT inference; not a direct replacement for all assays
News Market Reaction – CAI
On the day this news was published, CAI declined 3.63%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous AI Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 08 | AI signature launch | Positive | +4.0% | Introduced multimodal AI signature guiding chemo use in PD-L1 ≥50% NSCLC. |
| Mar 26 | AI risk models | Positive | -1.2% | Added AI Insights predicting brain metastases risk in breast and NSCLC. |
| Mar 16 | AI resistance marker | Positive | +3.5% | Launched AI signature identifying early platinum resistance in ovarian cancer. |
| Mar 09 | AI therapy guidance | Positive | +2.2% | Introduced AI signature to guide first-line and de-escalation in PDAC. |
| Feb 24 | AI chemo response | Positive | +3.2% | Added AI signature predicting capecitabine response in HER2‑negative breast cancer. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-tagged launches and signatures have usually seen modestly positive next-day moves, with one notable negative reaction.
Over recent months, Caris has repeatedly expanded its Caris AI Insights portfolio across multiple cancers, including NSCLC, breast, ovarian and pancreatic. These AI-driven signatures are delivered via MI Cancer Seek and the Molecular Tumor Board Report, leveraging WES/WTS and large multimodal datasets exceeding 500,000 patients. Historically, AI-related announcements produced mostly positive single-day price reactions. Today’s GBM-focused AI validation fits this pattern of broadening AI-enabled precision oncology capabilities.
Historical Comparison
Previous AI-related announcements for CAI led to an average 2.34% move, mostly positive. Today’s GBM-focused AI validation contrasts with that pattern given the -7.48% pre-news decline.
AI Insights have expanded from breast, lung, ovarian and pancreatic cancers into GBM, all leveraging MI Cancer Seek WES/WTS data and large clinico-genomic datasets to guide therapy selection and risk stratification.
Regulatory & Risk Context
Key Terms
ngs medical
mgmt promoter methylation medical
pyrosequencing medical
isocitrate dehydrogenase (idh)-wild type medical
kaplan-meier medical
clinico-genomic technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Caris AI Insights are proprietary and only available to Caris Life Sciences customers
Caris Life Sciences continues to advance precision oncology by integrating multimodal real-world datasets, available with its proprietary CodeAI™ platform, enabling the creation of Caris AI Insights, an engine that utilizes Whole Exome Sequencing (WES), Whole Transcriptome Sequencing (WTS), and clinical data to generate deeper biological understanding and more actionable insights for clinicians and researchers.
GBM is the most common and aggressive brain cancer, with patients typically surviving around 12 months despite treatment. Current treatments include surgery to remove the tumor, radiation and chemotherapy with temozolomide (TMZ). Unfortunately, nearly half of GBM patients do not respond to TMZ and many develop resistance that leads to recurrence. Determining whether TMZ will benefit the patient is a critical step in treatment and provides insight for developing new therapies for patients who do not respond favorably.
The novel signature, developed by Caris using multimodal molecular and clinical data, is an AI-derived model designed to infer O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status from NGS data. MGMT promoter methylation is an established biomarker associated with response to TMZ therapy in GBM patients that is commonly assessed using pyrosequencing. In the peer-reviewed validation study, the signature demonstrated high concordance with pyrosequencing-based MGMT assessment and improved discrimination of overall survival outcomes across MGMT-defined patient subgroups, while also addressing variability in MGMT classification associated with traditional testing methods. These findings show that Caris' proprietary AI signature can complement existing testing approaches and provide additional clinical insight for isocitrate dehydrogenase (IDH)-wild type GBM patients treated with TMZ.
"The Caris AI Insights signature for GBM showcases Caris' advanced AI capabilities in our pursuit of improving cancer patient outcomes," said Caris President David Spetzler, MS, PhD, MBA. "With peer-reviewed validation demonstrating strong concordance with traditional testing approaches and clearer prognostic stratification, we believe that this signature can complement existing testing methods to improve clinical insight for glioblastoma patients treated with TMZ."
The model was trained to predict MGMT promoter methylation status, as measured by a pyrosequencing assay, using tumor profiling data from the MI Cancer Seek NGS assay, which also has FDA-approved CDx indications. As reported in the study, the signature was developed using a clinico-genomic dataset of 5,841 patients and further evaluated in a prospective cohort of more than 3,400 cases. The model stratified patients into distinct survival groups based on the signature score, with higher scores associated with significantly longer overall survival in TMZ-treated patients.
About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer that is actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms at scale, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies, and high-performance computing provides a differentiated platform to develop the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.
Caris was founded with a vision to realize the potential of precision medicine in order to improve the human condition. Headquartered in
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases forward-looking statements can be identified by words such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or similar expressions.
You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: developments in the precision medicine industry; our future financial performance, results of operations or other operational results or metrics; development, analytical and clinical validation, timing and performance of future solutions by us and our competitors; commercial market acceptance for our solutions, including acceptance of preventive as well as diagnostic testing paradigms, and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions; risks related to data management, storage, and processing capabilities and our ability to integrate and deploy artificial intelligence and advanced data analytics technologies; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions; reliance on third-party suppliers; risks related to data security, patient privacy, and compliance with healthcare data protection regulations as well as potential cybersecurity threats to our data platforms; our compliance with laws and regulations; the outcome of government investigations and litigation; risks related to our indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" and elsewhere in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 3, 2026, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law.
Caris Life Sciences Media:
Corporate Communications
CorpComm@CarisLS.com
214.294.5606
View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-publishes-study-validating-caris-ai-insights-for-temozolomide-benefit-in-glioblastoma-patients-302756842.html
SOURCE Caris Life Sciences